1415110-10-9Relevant academic research and scientific papers
Synthesis method of imidacloprid metabolite 5-hydroxyimidacloprid
-
Paragraph 0053; 0059-0062, (2021/07/28)
The invention discloses a synthesis method of an imidacloprid metabolite 5-hydroxyimidacloprid, and belongs to the field of medicine synthesis. According to the synthesis method, methyl 5-hydroxynicotinate is used as a raw material, synthesis of the imidacloprid metabolite 5-hydroxylimidacloprid is achieved for the first time through six-step reaction, an optimal synthesis route and reaction conditions are screened out through a large number of experiments, the purity of the prepared target product can reach 99% or above, and the target product does not contain raw material medicine imidacloprid can be used for research on pharmacokinetics, raw material medicine impurity identification, environment control and protection and the like, provides a sample for impurity identification of imidacloprid, metabolic mechanism research, influence on the environment after medicine use, how to carry out corresponding protection and the like, and has important application value.
AROMATIC RING COMPOUND
-
Paragraph 0486, (2015/01/18)
Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of Type 2 diabetes mellitus
Pfefferkorn, Jeffrey A.,Tu, Meihua,Filipski, Kevin J.,Guzman-Perez, Angel,Bian, Jianwei,Aspnes, Gary E.,Sammons, Matthew F.,Song, Wei,Li, Jian-Cheng,Jones, Christopher S.,Patel, Leena,Rasmusson, Tim,Zeng, Dongxiang,Karki, Kapil,Hamilton, Michael,Hank, Richard,Atkinson, Karen,Litchfield, John,Aiello, Robert,Baker, Levenia,Barucci, Nicole,Bourassa, Patricia,Bourbounais, Francis,D'Aquila, Theresa,Derksen, David R.,MacDougall, Margit,Robertson, Alan
, p. 7100 - 7105 (2013/01/15)
Glucokinase activators represent a promising potential treatment for patients with Type 2 diabetes. Herein, we report the identification and optimization of a series of novel indazole and pyrazolopyridine based activators leading to the identification of 4-(6-(azetidine-1-carbonyl)-5-fluoropyridin-3- yloxy)-2-ethyl-N-(5-methylpyrazin-2-yl)-2H-indazole-6-carboxamide (42) as a potent activator with favorable preclinical pharmacokinetic properties and in vivo efficacy.
